Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Jacoby

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
International Journal of Geriatric Psychiatry|July 23, 2011
Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trialCeleste A de Jager, Abderrahim Oulhaj, Robin Jacoby, et al.
BMJ (Clinical Research Ed.)|March 18, 2006
Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trialJane Fossey, Clive Ballard, Edmund Juszczak, et al.
International Journal of Geriatric Psychiatry|June 2, 2009
Homocysteine as a predictor of cognitive decline in Alzheimer's diseaseAbderrahim Oulhaj, Helga Refsum, Helen Beaumont, et al.
International Journal of Geriatric Psychiatry|July 11, 2008
A pilot randomised controlled trial of a brief cognitive behavioural group intervention to reduce recurrence rates in late life depressionPhilip Wilkinson, Nicola Alder, Edmund Juszczak, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 22, 2013
Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatmentGwenaëlle Douaud, Helga Refsum, Celeste A de Jager, et al.
Plos Medicine|April 4, 2008
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)Clive Ballard, Marisa Margallo Lana, Megan Theodoulou, et al.
The Lancet. Neurology|January 14, 2009
The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trialClive Ballard, Maria Luisa Hanney, Megan Theodoulou, et al.
Plos One|September 15, 2010
Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trialA David Smith, Stephen M Smith, Celeste A de Jager, et al.
The Journal of Clinical Psychiatry|January 28, 2004
A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcomeClive G Ballard, Alan Thomas, Jane Fossey, et al.
BMJ (Clinical Research Ed.)|February 22, 2005
Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trialClive Ballard, Marisa Margallo-Lana, Edmund Juszczak, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
International Journal of Geriatric Psychiatry|July 23, 2011
Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trialCeleste A de Jager, Abderrahim Oulhaj, Robin Jacoby, et al.
BMJ (Clinical Research Ed.)|March 18, 2006
Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trialJane Fossey, Clive Ballard, Edmund Juszczak, et al.
International Journal of Geriatric Psychiatry|June 2, 2009
Homocysteine as a predictor of cognitive decline in Alzheimer's diseaseAbderrahim Oulhaj, Helga Refsum, Helen Beaumont, et al.
International Journal of Geriatric Psychiatry|July 11, 2008
A pilot randomised controlled trial of a brief cognitive behavioural group intervention to reduce recurrence rates in late life depressionPhilip Wilkinson, Nicola Alder, Edmund Juszczak, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 22, 2013
Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatmentGwenaëlle Douaud, Helga Refsum, Celeste A de Jager, et al.
Plos Medicine|April 4, 2008
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)Clive Ballard, Marisa Margallo Lana, Megan Theodoulou, et al.
The Lancet. Neurology|January 14, 2009
The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trialClive Ballard, Maria Luisa Hanney, Megan Theodoulou, et al.
Plos One|September 15, 2010
Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trialA David Smith, Stephen M Smith, Celeste A de Jager, et al.
The Journal of Clinical Psychiatry|January 28, 2004
A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcomeClive G Ballard, Alan Thomas, Jane Fossey, et al.
BMJ (Clinical Research Ed.)|February 22, 2005
Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trialClive Ballard, Marisa Margallo-Lana, Edmund Juszczak, et al.
Pageof 4